Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Opining the Slow Demise of Aspirin for Cardiovascular Disease

04/28/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings explores a new recommendation by the US Preventive Services Task Force to reduce aspirin use for the prevention of cardiovascular disease.

Dr Jennings explores a new...

04/28/2022

Pharmacy Learning Network

Talking Therapeutics

No ACE in the Hole for Advanced Chronic Kidney Disease

12/01/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings shares findings from a new study evaluating RAAS inhibitors for the treatment of advanced chronic kidney disease.

Dr Jennings shares findings from...

12/01/2022

Pharmacy Learning Network

Talking Therapeutics

Changing Treatment Pace for Heart Failure: Why We Shouldn’t Delay Guideline-Directed Medical Therapies

01/02/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings explores research that redefines the way health care professionals should approach treatment for patients with heart failure.

In the latest installment of...

01/02/2024

Pharmacy Learning Network

Talking Therapeutics

The Therapeutics of Resistant Hypertension

11/24/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings highlights research on dietary- and medication-related factors contributing to resistant hypertension in this week's Talking Therapeutics.

Dr Jennings highlights research...

11/24/2021

Pharmacy Learning Network

Talking Therapeutics

Dobutamine Shortage Woes: Examining Alternative Regimens

07/21/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the face of an impending shortage, Dr Jennings explores alternative options to dobutamine for treating cardiogenic shock.

In the face of an impending...

07/21/2022

Pharmacy Learning Network

Talking Therapeutics

More Than Meets the Eye With Melatonin Labeling?

05/02/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the latest installment of Talking Therapeutics, Dr Jennings shares new research into melatonin supplements which showed product labels were often inaccurate and did not reflect the actual quantities of melatonin included in each serving.

In the latest installment of...

05/02/2023

Pharmacy Learning Network

Talking Therapeutics

Advancing Decongestive Strategies in Acute Heart Failure

04/25/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings analyzes recent study findings determining efficacy of dapagliflozin in patients with acute heart failure.

In this installment of Talking...

04/25/2024

Pharmacy Learning Network

Talking Therapeutics

How to Talk to Patients About the COVID-19 Vaccines

03/03/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In the first installment, Dr Jennings breaks down the COVID-19 vaccines, and explains how to discuss them with patients.

In the first installment, Dr...

03/03/2021

Pharmacy Learning Network

Talking Therapeutics

"F" is for Fighting for the Future of Those With Diabetic Kidney Disease

02/10/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews data on finerenone, which showed efficacy in reducing kidney failure and death in patients with type 2 diabetes and advanced chronic kidney disease.

Dr Jennings reviews data on...

02/10/2022

Pharmacy Learning Network

Talking Therapeutics

Through Thick and Thin: Is Anticoagulation Warranted in COVID-19 Infection?

11/03/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings reviews data from three recently published papers regarding what symptoms and conditions make anticoagulants a viable treatment option for patients with COVID-19.

This week, Dr Jennings reviews...

11/03/2021

Pharmacy Learning Network